Thyrocare Technologies
NSE: THYROCARE · ISIN INE594H01019 · Healthcare
₹488.05−10.90 (−2.18%)
Monday 9 November, 13:31 IST. Delayed. Source: Yahoo Finance.
Price chart
₹488.05 −10.90 (−2.18%) today
The day
- Previous close
- ₹498.95
- Open
- ₹501.40
- Day high
- ₹506.05
- Day low
- ₹465.60
Listed on NSE since 9 May 2016.
Key numbers
- Market value
- ₹7,848.44 Cr
- P/E (trailing)
- 54.97
- EPS (trailing)
- ₹8.97
- Price to book
- 14.75
- Dividend yield
- 1.89%
- Return on equity
- 26.4%
- Debt to equity
- 0.10
- Profit margin
- 15.5%
- Beta
- 0.50
- Volume today
- 10.14 L
- Average volume
- 5.61 L
Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.
Revenue and profit
| Year | Revenue | Net profit |
|---|---|---|
| FY23 | ₹517.20 Cr | ₹64.49 Cr |
| FY24 | ₹567.88 Cr | ₹70.76 Cr |
| FY25 | ₹680.71 Cr | ₹91.51 Cr |
| FY26 | ₹821.89 Cr | ₹163.04 Cr |
Source: Yahoo Finance, from annual reports. Consolidated where reported.
Quarterly results
| Quarter | Revenue | Net profit | Profit vs year ago |
|---|---|---|---|
| Q2 FY27Jul–Sep 2026 | ₹271 Cr | ₹16 Cr | −66.9% |
| Q1 FY27Apr–Jun 2026 | ₹240 Cr | ₹52 Cr | +34.1% |
| Q4 FY26Jan–Mar 2026Audited | ₹224 Cr | ₹47 Cr | +117.1% |
| Q3 FY26Oct–Dec 2025 | ₹196 Cr | ₹29 Cr | – |
| Q2 FY26Jul–Sep 2025 | ₹217 Cr | ₹48 Cr | – |
| Q1 FY26Apr–Jun 2025 | ₹193 Cr | ₹39 Cr | – |
Source: Thyrocare Technologies’s results filed with NSE, consolidated (the whole group). Net profit is the share of Thyrocare Technologies’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss. EPS before Q3 FY26 is not shown: the share count changed (a bonus, split or merger), so it would not compare.
Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.
Balance sheet
| As on | September 2026 | March 2026 |
|---|---|---|
| Fixed assets | ₹223 Cr | ₹209 Cr |
| Investments | ₹142 Cr | ₹152 Cr |
| Inventories | ₹49 Cr | ₹48 Cr |
| Owed by customers | ₹89 Cr | ₹74 Cr |
| Cash and equivalents | ₹22 Cr | ₹38 Cr |
| Total assets | ₹725 Cr | ₹747 Cr |
| Borrowings | ₹0 | ₹0 |
| Total liabilities | ₹173 Cr | ₹161 Cr |
| Shareholders’ equity | ₹553 Cr | ₹586 Cr |
Source: Thyrocare Technologies’s half-yearly statements of assets and liabilities filed with NSE, consolidated. Companies file these every September and March.
About Thyrocare Technologies
Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. It operates through three segments: Diagnostic Testing Services, Imaging Services, and Others. The Diagnostic Testing Services segment engages in the selling of consumables used for collection, and promotion of pathology. The Imaging Services segment sells radio-pharmaceutical and consumables for reporting. The Others segment engages in the sale of glucometer and glucostrips under the brand name sugarscan. The company offers diagnostic and pathological services. The company was founded in 1996 and is based in Navi Mumbai, India. Thyrocare Technologies Limited is a subsidiary of Docon Technologies Private Limited.
- Industry
- Diagnostics & Research
- Based in
- Navi Mumbai
- Employees
- 1,906
Company website · Profile: Yahoo Finance
In the news
All newsNo headlines name Thyrocare Technologies in the last day or two.
Dividends and corporate actions
All companies- Dividend - Rs 7 Per Share
Dividend · ex-date 23 June 2026
- Bonus 2:1
Bonu · ex-date 28 November 2025
- Interim Dividend - Rs 7 Per Share
Dividend · ex-date 24 October 2025
- Dividend - Rs 21 Per Share
Dividend · ex-date 25 July 2025
- Dividend - Rs 18 Per Share
Dividend · ex-date 16 August 2024
- Interim Dividend - Rs 18 Per Share
Dividend · ex-date 20 April 2023
- Annual General Meeting
Action · ex-date 25 July 2022
- Interim Dividend - Rs 15 Per Share
Dividend · ex-date 11 May 2022 · record date 12 May 2022
Source: NSE. Latest first, 8 of 17.
Information only, not investment advice. Prices are delayed.